INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 45h ago
HOUSE PTR5h ago
SEC 13F5h ago
ROBINHOOD CHAIN5h ago
SEC FORM 4/Open-market saleVerified data

Renninger Robert sold ATHA

Chief Financial Officer · LeonaBio, Inc. · Athira Pharma, Inc.

Side
SELL
Value
$2,043
Shares
297
Price
$6.88
Executed
Jan 2, 2026
Disclosed
Jan 5, 2026
Disclosure timeline3 days from execution to publication · legal deadline 2 business days
Jan 2 executedJan 5, 2026 disclosed

ATHA · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
31/ 100 · ELEVATED
Methodology →
  • Transaction type+12 / 20

    Open-market sale

  • Relative size+1 / 25

    $2K reported value · 2.3% of prior position

  • Filing timing0 / 15

    Disclosed 1 business day after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events+10 / 10

    Officer or director change · Other material event filed 7 days after the trade (8-K)

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · ATHA

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    53
    PJ
    Portman David J.10% Owner
    LONALeonaBio, Inc.
    Open-market purchase
    		BUY$9.92B
    3.15M sh
    		Oct 26, 2026Oct 28, 2026
    traded Oct 26, 2026
    		+2dSEC FORM 4

    Evidence

    53
    PJ
    Portman David J.10% Owner
    LONALeonaBio, Inc.
    Open-market purchase
    		BUY$17.33B
    5.50M sh
    		Oct 26, 2026Oct 28, 2026
    traded Oct 26, 2026
    		+2dSEC FORM 4

    Evidence

    9
    SB
    Silverman Peter B.Director
    LONALeonaBio, Inc.
    Grant or award
    		A—
    2,333 sh
    		Jun 23, 2026Jun 24, 2026
    traded Jun 23, 2026
    		+1dSEC FORM 4

    Evidence

    9
    KB
    Kosacz BarbaraDirector
    LONALeonaBio, Inc.
    Grant or award
    		A—
    28.0K sh
    		Jun 23, 2026Jun 24, 2026
    traded Jun 23, 2026
    		+1dSEC FORM 4

    Evidence

    9
    RA
    Romano Kelly ADirector
    LONALeonaBio, Inc.
    Grant or award
    		A—
    28.0K sh
    		Jun 23, 2026Jun 24, 2026
    traded Jun 23, 2026
    		+1dSEC FORM 4

    Evidence

    9
    CF
    Callori FredDirector
    LONALeonaBio, Inc.
    Grant or award
    		A—
    2,333 sh
    		Jun 23, 2026Jun 24, 2026
    traded Jun 23, 2026
    		+1dSEC FORM 4

    Evidence

    9
    CF
    Callori FredDirector
    LONALeonaBio, Inc.
    Grant or award
    		A—
    56.0K sh
    		May 5, 2026May 7, 2026
    traded May 5, 2026
    		+2dSEC FORM 4

    Evidence

    9
    SB
    Silverman Peter B.Director
    LONALeonaBio, Inc.
    Grant or award
    		A—
    56.0K sh
    		May 5, 2026May 7, 2026
    traded May 5, 2026
    		+2dSEC FORM 4

    Evidence

    9
    WM
    Worthington MarkGENERAL COUNSEL and CCO
    LONALeonaBio, Inc.
    Grant or award
    		A—
    300.0K sh
    		Apr 9, 2026Apr 13, 2026
    traded Apr 9, 2026
    		+4dSEC FORM 4

    Evidence

    9
    SJ
    San Martin JavierCHIEF MEDICAL OFFICER
    LONALeonaBio, Inc.
    Grant or award
    		A—
    350.0K sh
    		Apr 9, 2026Apr 13, 2026
    traded Apr 9, 2026
    		+4dSEC FORM 4

    Evidence

    9
    LJ
    Litton Mark JamesDirector, PRESIDENT and CEO
    LONALeonaBio, Inc.
    Grant or award
    		A—
    750.0K sh
    		Apr 9, 2026Apr 13, 2026
    traded Apr 9, 2026
    		+4dSEC FORM 4

    Evidence

    5
    RR
    Renninger RobertCHIEF FINANCIAL OFFICER
    LONALeonaBio, Inc.
    Grant or award
    		A—
    300.0K sh
    		Apr 9, 2026Apr 13, 2026
    traded Apr 9, 2026
    		+4dSEC FORM 4

    Evidence

    9
    CK
    Church KevinCHIEF SCIENTIFIC OFFICER
    LONALeonaBio, Inc.
    Grant or award
    		A—
    300.0K sh
    		Apr 9, 2026Apr 13, 2026
    traded Apr 9, 2026
    		+4dSEC FORM 4

    Evidence

    9
    KB
    Kosacz BarbaraDirector
    LONALeonaBio, Inc.
    Grant or award
    		A—
    28.0K sh
    		Apr 9, 2026Apr 13, 2026
    traded Apr 9, 2026
    		+4dSEC FORM 4

    Evidence

    9
    RA
    Romano Kelly ADirector
    LONALeonaBio, Inc.
    Grant or award
    		A—
    28.0K sh
    		Apr 9, 2026Apr 13, 2026
    traded Apr 9, 2026
    		+4dSEC FORM 4

    Evidence

    9
    PA
    Panzara Michael A.Director
    LONALeonaBio, Inc.
    Grant or award
    		A—
    28.0K sh
    		Apr 9, 2026Apr 13, 2026
    traded Apr 9, 2026
    		+4dSEC FORM 4

    Evidence

    13
    RR
    Renninger RobertCHIEF FINANCIAL OFFICER
    LONALeonaBio, Inc.
    Option exercise
    		M—
    3,900 sh
    		Mar 3, 2026Mar 5, 2026
    traded Mar 3, 2026
    		+2dSEC FORM 4

    Evidence

    31
    RR
    Renninger RobertCHIEF FINANCIAL OFFICER
    LONALeonaBio, Inc.
    Open-market sale
    		SELL$4,865
    906 sh
    		Mar 4, 2026Mar 5, 2026
    traded Mar 4, 2026
    		+1dSEC FORM 4

    Evidence

    5
    RR
    Renninger RobertCHIEF FINANCIAL OFFICER
    LONALeonaBio, Inc.
    Option exercise
    		M—
    3,900 sh
    		Mar 3, 2026Mar 5, 2026
    traded Mar 3, 2026
    		+2dSEC FORM 4

    Evidence

    15
    RR
    Renninger RobertChief Financial Officer
    ATHALeonaBio, Inc.
    Option exercise
    		M—
    1,236 sh
    		Dec 31, 2025Jan 5, 2026
    traded Dec 31, 2025
    		+5dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002037968-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jan 2, 2026
    Published
    Jan 5, 2026
    Ingested by INSIDER
    Nov 5, 04:24 UTC
    Last re-read
    Nov 5, 04:24 UTC

    Extracted facts

    Filer
    Renninger Robert
    Role
    Chief Financial Officer
    Transaction
    Open-market saleAs filed: “S”
    Asset
    Athira Pharma, Inc.
    Ticker
    ATHA
    Shares
    297
    Price per share
    $6.88
    Value
    $2,043
    Execution date (reported)
    Jan 2, 2026
    Owned after transaction
    12.9K shares
    Days from execution to publication
    3

    Calculation

    Value = shares × reported price per share

    • Shares: 297
    • Price: $6.88

    = $2,043

    What this establishes

    Renninger Robert filed this Form 4 reporting a open-market sale of ATHA on Jan 2, 2026. It became public on Jan 5, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Financial Officer
    Renninger Robertcik:0002037968
    Issuer
    LeonaBio, Inc.cik:0001620463

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    • Other material event8-KSep 22, 2026
    • Other material event8-KAug 26, 2026
    • Quarterly report (10-Q)10-QAug 14, 2026
    • Results of operations (earnings)8-KAug 14, 2026
    • Quarterly report (10-Q)10-QMay 7, 2026
    • Results of operations (earnings)8-KMay 7, 2026
    • Annual report (10-K)10-KMar 31, 2026
    • Results of operations (earnings)8-KMar 26, 2026
    • Officer or director change · Other material event8-KMar 19, 2026
    • Officer or director change · Other material event8-KJan 9, 2026
    • Entry into a material agreement · Other material event8-KDec 18, 2025
    • Quarterly report (10-Q)10-QNov 6, 2025
    • Results of operations (earnings)8-KNov 6, 2025
    • Other material event8-KOct 3, 2025
    Source error

    Price history for ATHA is unavailable.

    An error occurred in the Server Components render. The specific message is omitted in production builds to avoid leaking sensitive details. A digest property is included on this error instance which may provide additional details about the nature of the error.